[
    [
        {
            "time": "",
            "original_text": "复星医药：控股子公司凯茂生物受让产品临床批件",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "凯茂生物",
                    "临床批件"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：控股子公司凯茂生物受让产品临床批件",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "5300亿的复星，大手笔布局医疗器械圈！",
            "features": {
                "keywords": [
                    "复星",
                    "医疗器械",
                    "布局",
                    "投资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "5300亿的复星，大手笔布局医疗器械圈！",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业动态：国务院发文促进仿制药研发、生产和使用",
            "features": {
                "keywords": [
                    "国务院",
                    "仿制药",
                    "研发",
                    "生产",
                    "使用"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业动态：国务院发文促进仿制药研发、生产和使用",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "业绩",
                    "创新",
                    "升级"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "Q2季度",
                    "创新",
                    "升级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]